Scotiabank analyst Sung Ji Nam maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $37 to $44.
According to TipRanks data, the analyst has a success rate of 49.0% and a total average return of -0.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences delivered robust financial performance with another quarter surpassing expectations and achieving GAAP profit for the second time in a row. The stock presents a favorable risk/reward scenario. There is a strong possibility that Medicare reimbursement for the company's squamous cell carcinoma test may be extended beyond the fourth quarter, as payment has been received for the test over the last two and a half years and the company has effectively gathered additional supporting evidence and data.
Castle Biosciences reported a solid third quarter, with revenues meeting expectations and encouraging operational expenditure leverage. The overall volume growth was noted, although dermatology volumes fell short of estimates due to seasonal factors. Additionally, TissueCypher continued to show impressive momentum.
The expectation for Castle Biosciences is that although the coverage determination for the SCC test will stay as a point of interest, the company is experiencing expansion in test volumes, notably in IDgenetix and TissueCypher. This expansion in test volumes has played a significant role in the company's robust quarterly performance and the subsequent elevation of its revenue forecast.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
豐業銀行分析師Sung Ji Nam維持$Castle Biosciences (CSTL.US)$買入評級，並將目標價從37美元上調至44美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.0%，總平均回報率為-0.4%。
此外，綜合報道，$Castle Biosciences (CSTL.US)$近期主要分析師觀點如下：
Castle Biosciences實現了強勁的財務業績，又一個季度超出了預期，連續第二次實現了GAAP利潤。該股呈現出有利的風險/回報情景。該公司鱗狀細胞癌測試的醫療保險報銷很有可能延長到第四季度以後，因爲在過去兩年半中已經收到了該測試的款項，而且該公司實際上已經收集了額外的支持證據和數據。
Castle Biosciences公佈了穩健的第三季度業績，收入符合預期，運營支出槓桿率令人鼓舞。儘管由於季節性因素，皮膚科數量低於預期，但總體銷量仍有增長。此外，TissueCypher繼續表現出令人印象深刻的勢頭。
對Castle Biosciences的預期是，儘管SCC測試的覆蓋範圍決定仍將是人們關注的焦點，但該公司的測試量正在擴大，尤其是IDGenetix和TissueCypher的測試量。測試量的增長在公司強勁的季度業績以及隨後提高收入預測方面發揮了重要作用。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
